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Summary Acrodermatitis continua of Hallopeau (ACH) is a rare manifestation of pustular psoriasis which may
considerably disable affected patients. In this case report we confirm the efficacy of acitretin in the 
treatment of ACH and, in addition, describe the course of the myelodysplastic syndrome (MDS) from 
which the patient was suffering. During acitretin treatment, there was a transformation into acute 
myeloid leukaemia. We discuss the effect of retinoids on the bone marrow of normal subjects, 
patients with AIDS, and patients with acute myeloid leukaemia.
Our experience in the present case, and the information from the available literature, lead us to 
advise against the use of the aromatic retinoids, acitretin and etretinate, in patients with MDS. If 
such treatment is indicated, intensive haematological supervision is mandatory.
Acrodermatitis continua of Hallopeau (ACH) is a rare 
type of localized pustular psoriasis. The condition is 
characterized by the occurrence of pustules on the fingers 
and toes. Systemic antipsoriatic treatments are indicated 
in ACH. Although no controlled studies are available, 
ACH is reported to respond well to systemic cortico-
1_Q
steroids, methotrexate, acitretin, and cyclosporin.
Recently, we have treated a patient with ACH, who 
also had a myelodysplastic syndrome (MDS) with a 
refractory anaemia (RA) and a severe thrombocyto­
penia. The severity of the ACH necessitated systemic 
treatment, and the patient was given acitretin with 
careful monitoring of the blood parameters.
Case report
In 1989, a 53-year-old man presented with an erythe- 
matosquamous and pustular eruption of the toes. 
Haematological investigation showed severe thrombo­
cytopenia (platelet count 5-20 x 199/1), and a bone 
marrow examination was hypercellular, with myelo- 
displasia, and a low number of megakaryocytes. The 
disorder was classified as MDS, RA-type since there 
were normal blast counts. HLA typing revealed: -A3, 
-A28, B27, -B35, -CW1, and -CW4. Treatment was 
started with methylprednisolone, 50 mg/day. Although 
the skin condition showed some improvement with this
thrombocytopenia
ß
mg/day and-propranolol, 40 mg three times
because of a supraventricular tachycardia, and he 
took omeprazole for gastrointestinal discomfort and 
bleeding.
ACH, with chronic plaque psoriasis, was diagnosed, 
and the patient was treated with low-dose methotrex­
ate, firstly at a dose of 5 mg/week and, later, 10 mg/ 
week. Methylprednisolone was continued, at a dosage 
of 2 5 mg/day and, in addition, the patient used potent 
topical corticosteroids.
Episodes of epistaxis, purpura, and gastrointestinal 
bleeding required frequent transfusions of blood and 
platelets. Cytogenetic investigations showed trisomy 
10, which confirmed the diagnosis of MDS. Methotrex­
ate, methylprednisolone and propranolol were stopped. 
Treatment was started with interleukin (IL)-3, at a 
dosage of 10/ig/kg per day. According to the EORTC 
protocol for MDS, IL-3 was stopped, after 3 weeks, 
because of fever, loss of appetite, and general malaise. 
During this treatment, the patient’s skin condition got 
worse and required additional treatment.
Examination showed well-demarcated, erythemato- 
squamous lesions, covered with yellow crusts, on three 
fingers of the right hand, and on all 10 toes (Fig. 1). A 
paronychia and distal onycholysis of the first finger of 
the left hand, was present. On the soles, scalp and neck, 
there were well-demarcated erythematosquamous pla­
ques, with a psoriasiform appearance. In the interglu- 
teal area, a well-demarcated erythema was seen. On the 
buttocks and upper legs there was purpura. Cultures for 
fungi were negative.
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Figure 1. Crusted, erythematous, pustular 
lesions are present on the toes.
In January 1992, acitretin (Neotigason; Hoffman 
LaRoche) was started, at a dosage of 35 mg/day (the 
patient weighed 84 kg). Topical treatment with corti­
costeroids and tar preparations was continued. After 2 
weeks of treatment, a substantial improvement was 
seen (Fig. 2). Subsequently, the dosage of acitretin 
was increased to 40mg/day, and there was a mild 
cheilitis, indicating that the dosage was sufficient. 
During subsequent months, the skin condition 
improved further, to the extent that only minimal 
residual changes persisted. During the 7 months of 
treatment with acitretin, at a dosage of 3 5-40 mg/ 
day, no side-effects, apart from mild cheilitis, were
recorded. The serum cholesterol, triglycerides, and 
transaminases remained within the normal range. No 
j oint complaints were recorded.
However, during this period, clinically evident bleed­
ing from the gastrointestinal tract necessitated platelet 
transfusions. The frequency of these transfusions was 
comparable to that in the period before treatment with 
acitretin. The platelet counts remained in the same 
range as before treatment with acitretin, i.e. 5— 
40 x 10 /1. In February 1992, anaemia developed, 
and a gradual increase in the leucocyte and blast 
counts was seen. In May 1992, whilst the patient 
was still on treatment with acitretin, acute myeloid
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Figure 2. Residual erythema of the toes is 
seen after 2 weeks of treatment with 
acitretin (35 mg/day).
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leukaemia was diagnosed. An MDS high-risk regimen 
(EORTC), with idarubicin and Ara C, was instituted. 
After the first course, complete remission was not 
obtained and a pancytopenia persisted. During the 
second remission-induction course, the patient died, 
after 5 weeks, due to cerebral bleeding.
Discussion
Although there are no placebo-controlled studies for 
acitretin in ACH, the use of acitretin in localized and 
generalized pustular psoriasis is well established. So far, 
there are only two case reports on the treatment of 
ACH.2,9 Our report confirms the efficacy of acitretin in 
this rare condition. The decision to initiate treatment 
with acitretin was justified by the severe and disabling 
symptoms, but was complicated by the coexistence of 
MDS, which necessitated intensive haematological 
supervision. The published literature is not clear as to 
whether treatment with systemic retinoids is allowed 
or contraindicated in patients with MDS. Studies in the 
1920s reported a reduction of haematopoietic cells in 
the bone marrow of vitamin A-depleted animals.
In human vitamin A deficiency, moderate anaemia 
develops despite ample dietary sources of all essential 
nutrients except the vitamin A. Etretinate, the ester of
10,11
acitretin (at 10 to 10-/ mol/1) has been reported 
to increase the clone size of colony-forming unit- 
granulocyte macrophage (CFU-GM) from normal human 
bone marrow, in contrast to the inhibitory effect of 13- 
cis-retinoic acid.13 The effects of retinoids on the normal 
bone marrow are not well understood.
Several reports in the literature indicate that retinoids 
have a beneficial effect on the course of MDS. Clark et al. 
reported a significant increase in the 1-year survival, 
from 30 to 77%, in the treated group in non-side- 
roblastic patients, and no significant effect in patients 
with sideroblastic anaemia.14 Koeffler et al. did not find 
a significant response in patients with MDS.
7
IS
the patients in this group had either high-risk disease or 
sideroblastic anaemia. In these, the result of Clark et al 
also indicate no significant improvement.15 In cultures 
from patients with MDS, 20 of 34 cases showed greater 
inhibition of total colony numbers than controls, and 
some patients proved to have greater sensitivity than 
normal subjects with respect to the inhibitory effect of 
retinoic acid.15 In short-term liquid cultures of bone 
marrow from 13 patients with MDS, 13-cis-retinoic acid 
induced a significant decrease in the number of pro­
myelocytes and Leu-M3 positive cells. Hence, retinoids 
seem to induce a shift from monocytoid to myeloid
differentiation. However, etretinate in culture did not 
show any capacity to induce differentiation. i  f t
has been 
disorder which, in
Malignant transformation in 
described.17-20 MDS is a stem cell 
30% of the patients, progresses to acute myeloid 
leukaemia. Expansion of the abnormal cell population 
is accompanied by selection of subclones with a growth 
advantage, resulting in leukaemia. Do retinoids contri­
bute to this leukaemic transformation? Breitman et al. 
found that retinoic acid induces promyelocytic leukae­
mia cells to differentiate into functionally mature 
granulocytes.21,2 Others have shown that this
rentiation of er o-induces erythroid
J  )
leukaemia cells." In contrast to growth stimulation of 
normal haematopoietic progenitor cells, retinoid acid 
inhibited the proliferation of myeloid leukaemic 
blasts. Retinoic acid appears to act directly on the 
myeloid pregenitors, probably by increasing the respon­
siveness of these cells to the action of colony-stimulating 
factor." All-ira/zs-retinoic acid was shown to induce 
differentiation in patients with acute promyelocytic
^  f  ^  « y  ^  n
leukaemia." Flynn et al.“ and Nilsson" both describe 
patients with promyelocytic leukaemia in whom incu­
bation of immature blood cells with retinoic acid in vitro 
resulted in maturation, and treatment with retinoic acid 
resulted in maturation of blood cells together with a 
temporary clinical remission. In 1988, Meng-re et al. 
described 24 patients with promyelocytic leukaemia
who were treated with all-trans retinoic 29 All
patients showed complete remission and, in 14 of the 
15 patients in whom in vitro studies were carried out, 
morphological maturation of blood cells was shown.29 
Similar results were reported by Castaigne et al. 30 The
role of acitretin and its ester, etretinate, in the develop­
ment of promyelocytic cell lines and leukaemia is less 
clear. Several authors report etretinate to be unable to 
induce
31 - 3 3
ation in U-937 and 111,-60 cell 
lack of efficacy, in contrast to 
effect of iill-trans retinoic acid, was shown in the case
of acute promyelocytic leukaemia. 1 Conversely, some 
reports suggest that retinoids might have an unfavour­
able effect on the course of leukaemia. Lawrence et al.55 
noted that, in some patients with acute myeloblastic 
leukaemia, clonal growth of CFU-GM in vitro was 
stimulated sometimes by retinoic acid, and that in vivo 
the effect may vary from patient to patient. Awareness 
of the deleterious effect of retinoid therapy is important 
in patients who have the more malignant variants of 
MDS. Garewal et al. noticed acceleration of disease in 
two out of 15 patients with MDS who were treated
fenretinide [N-(4-hydroxyphenyI) retinoid 3 h
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In our patient, transformation into acute myeloid 
leukaemia occurred shortly after treatment with acitretin 
was started. We are unaware of any other cases of MDS 
showing this type of transformation during acitretin 
treatment. MDS should not be regarded as an absolute 
contraindication for treatment with retinoids, but
, intensiveif patients with this disorder are 
haematological supervision is indicated.
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